Dr. Kathryn E. Hudson, MD

Dr. Hudson practices at Texas Oncology PA in Austin, Texas.

Dr. Hudson's NPI, 1194987776, was assigned on June 25, 2008. Dr. Hudson graduated from Perelman School of Medicine - Philadelphia in 2008. Dr. Hudson holds Texas license Q7561.

Dr. Hudson's primary practice is Texas Oncology PA, at 6204 Balcones Dr, Austin, TX 78731 in Travis County. The practice phone is (972) 997-8000.

Dr. Hudson's primary practice is Texas Oncology PA in Austin, Texas. Dr. Hudson is also affiliated with St. David's Medical Center. The medical group on file is Texas Oncology. Dmand AI also links Dr. Hudson to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hudson practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Hudson's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Hudson is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Hudson's licenses on file in 3 states: Texas, North Carolina and Pennsylvania.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer, lymphoma and multiple myeloma among the conditions Dr. Hudson treats.

CMS data shows 75,243 Medicare services from Dr. Hudson across 71 procedure codes in 2024, for 612 Medicare patients. Medicare paid $1,015,716 for them.

CMS counts 612 Medicare patients who saw Dr. Hudson in 2024. The largest group is 65 to 74, with 289 patients. 70% of them have high cholesterol, and 66% have high blood pressure. 4% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hudson's median patient age at 66, with 68% women.

In 2024, Dr. Hudson wrote 1,277 Medicare Part D claims for 219 patients. 64% of them were for generic drugs. CMS names the drug for 978 of them, across 32 drugs with 11 or more claims each, at $2,846,935 in total drug cost. In 2023, CMS named 932 claims across 30 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Hudson for performance year 2024, reported through an alternative payment model (APM). Dr. Hudson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hudson as offering telehealth.

Dmand AI links 8 papers to Dr. Hudson, published from 2018 to 2023. 2018 was the busiest year, with 2. The most frequent topics are Electronics, Patient Reported Outcome Measures and Breast Neoplasms. Dr. Hudson has published most often in JCO Clin Cancer Inform. Dr. Hudson's most frequent co-authors are Thomas William Leblanc, MA, MD, Ethan M. Basch, MD and Debra Ann Patt, MD, MPH.

CMS Open Payments shows 70 general payments to Dr. Hudson from 17 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 84% of the total. Daiichi Sankyo Inc. paid the most, $10,896. It also lists 2 research payments totaling $952 in 2022.

Dr. Hudson graduated from Perelman School of Medicine - Philadelphia in 2008.

Dr. Hudson is in network with 24 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.